AstraZeneca Faces Setback From Lung Cancer Drug's Disappointing Trial Results

KEY TAKEAWAYSA Phase 3 trial found AstraZeneca's experimental lung cancer drug datopotamab deruxtecan did not significantly improve patients' overall survival rates.The results from the trial showed that the overall survival rate "did not reach statistical significance," the company said.AstraZeneca shares fell in early trading Tuesday following the news, before recovering later in the session. A Phase 3 trial found AstraZeneca's (AZN) experimental lung cancer drug datopotamab deruxtecan (Dato-DXd) did not ...